Just Another Manic Monday

Just Another Manic Monday

Presented by

NEWS
Just Another Manic Monday

Source: Tenor.com

Markets kicked off the week with mixed performance, as the Dow Jones outperformed on strength in basic materials, energy, and healthcare stocks. Meanwhile, quantum computing names saw a sharp selloff, with many plunging over 20% in a single session. Broader market sentiment remained cautious, with rising concerns over 10-year bond yields nearing 5% and Bitcoin flirting with the $90,000 level again. 👀

Today’s issue covers what caused a major move in healthcare stocks, how retail’s approaching retail names during earnings, and many more pops and drops. 📰

Here’s the S&P 500 heatmap. 9 of 11 sectors closed green, with materials (+2.23%) leading and utilities (-1.16%) lagging.

Source: Finviz.com

And here are the closing prices: 

S&P 500

5,836

+0.16%

Nasdaq

19,088

-0.38%

Russell 2000

2,194

+0.24%

Dow Jones

42,297

+0.86%

Most bullish/bearish symbols on Stocktwits at the close: 📈 $PHIO, $KAPA, $MOS, $BDTX, $LAB 📉 $EIX, $PCG, $HE, $AEO, $AGEN*

*If you’re a business and want to access this data via our API, email us.

COMPANY NEWS
A Big Day For Healthcare Stocks 🏥 

Insurers who administer private Medicare plans could see a $21 billion payday in 2026 under a plan proposed by the Biden administration.

The proposal would raise the plans’ base payment by about 2% net year, but insurers would likely get an average 4.3% increase in overall revenue after certain adjustments. And with the Biden admin previously challenging these companies over costs, many believe Trump’s adjustments could be even more beneficial. 📊 

The Centers for Medicare and Medicaid Services (CMS) will accept comments on the payment proposal through Feb. 10. However, the Trump administration has to take on releasing a final policy for 2026 by April 7.

Managed care stocks like CVS, UnitedHealth, and Humana all rose on the news. Stocktwits sentiment toward these stocks pushed into ‘bullish’ or ‘extremely bullish’ territory, as traders looked to play a continued healthcare bounce. 🐂 

Source: Stocktwits.com

Additionally, several other healthcare stocks were in the news: 📰 

Moderna (-17%): The vaccine maker lowered its 2025 sales guidance by about $1 billion, citing a challenging outlook in the COVID-19 vaccine market.

Intra-Cellular Therapies (+34%): The biotech firm will be acquired by Johnson & Johnson (JNJ) in a $14.6 billion cash deal, at a 40% premium to its latest close.

Sage Therapeutics (+37%): The biotech stock reached its highest level since October following confirmation of an unsolicited takeover bid from Biogen Inc.

Phio Pharmaceuticals (+294%): This explosive move followed the announcement of positive results from a Phase 1b trial of its cancer treatment, PH-762, which is designed to enhance the immune system’s ability to target tumors.

Eli Lilly (-1%): CEO David Ricks said the company expects its experimental weight loss pill to be approved as soon as early next year, as it races against Novo Nordisk and smaller rivals to secure its share of the booming weight loss drug market.

SPONSORED
StockVerse Exclusive: The $16 Biotech Stock Investors Can’t Ignore

Meet Cadrenal Therapeutics (CVKD), recognized as 2024’s “Anticoagulation Therapy Company of the Year.”

Their drug, Tecarfarin, could potentially outperform Warfarin through a unique metabolic pathway—promising fewer side effects and more stable dosing.

With Orphan Drug & Fast Track designations plus a planned Phase 3 trial in 2025, if approved CVKD may see considerable upside.

Also try StockVerse GPT—imagine ChatGPT meets real-time stock data: stockverse.com/stockverse-gpt.

Best,

Mark – StockVerse

*3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here. Disclaimer: Paid ad by Relqo Media LLC, compensated up to $200,000 by Penzance LLC for Cadrenal Therapeutics (CVKD). Not investment advice. We own no shares and won’t trade shares. Use at your own risk. Investing involves risks, including loss of principal. Past performance not guaranteed. Always consult a licensed financial professional. More at stockverse.com/disclaimer.

COMPANY NEWS
Retailers React To Retailers’ Reaction 🤔 

Now THAT’s a confusing title, but bear with us here. Retail companies were out in full force today, providing investors an update on their holiday shopping quarter.

Lululemon, Abercrombie & Fitch, and American Eagle all raised their fourth-quarter outlooks on Monday, showcasing a strong response from shoppers, but their shares did not fare as well as many expected given the “good” news. 🙃 

Abercrombie raised its own guidance, but not enough to meet Wall Street’s sky-high expectations…sending shares down 16%. Macy’s was among the losers, falling over 8% after warning that its quarterly results would be worse than initially anticipated.

Clearly it’s going to be a wild ride for retail stocks this quarter, but retail investors and traders are staying involved. A newly-posted poll of Stocktwits users shows 62% of respondents believe the consumer is strong, and that retail stock weakness is something to buy on the dips. 🛒 

Source: Stocktwits.com

P.S. did you know you can now comment on polls? It’s the perfect way to share your rationale, ask questions, and continue the disucssion. You can also follow the @StocktwitsPolls account on platform for a feed of all the latest polls! 🗳️ 

If you can’t see the comment feature yet, don’t fret! The update is rolling out across web and iOS as we speak, but we can’t wait to have you try it! 😀 

STOCKS
Other Noteworthy Pops & Drops 📋️ 

Gorilla Technology (+5%): Following a board meeting over the weekend, the company boosted its share buyback program from $6 million to $10 million. It also raised concerns about potential manipulation of its stock price.

IAC (+4%): The company’s board approved the spinoff of Angi, the home improvement marketplace it acquired in 2017.

Edison International (-12%): Shares fell to their lowest level in over two years after CEO Pedro Pizarro said the company could not “rule out” the possibility that its infrastructure played a role in sparking wildfires currently burning near Los Angeles.

PG&E Corp. (-6%): BMO Capital initiated coverage with an ‘Outperform’ rating and a $21 price target. It described PG&E as a strong investment within the regulated utility sector, citing a combination of high growth potential and compelling valuation.

U.S. Steel (+6%): A CNBC report surfaced of a potential bid involving Cleveland-Cliffs Inc. (CLF) and Nucor Corp. (NUE), barely a week after the White House blocked a $14 billion takeover attempt by Japan’s Nippon Steel.

Barrick Gold (-2%): Reports emerged that Mali’s military junta has begun enforcing an interim order to seize gold stockpiles at the company’s Loulo-Gounkoto mine.

Range Resources (+1%): BofA Global Research upgraded the natural gas producer to ‘Buy’ from ‘Neutral,’ raising the stock’s price target from $34 to $45.

Snow Lake Resources (+15%): The natural resource exploration company announced the discovery of high-grade gallium in Ontario, Canada.

Aehr Test Systems (-18%): Announced its first AI processor customer for wafer level burn-in, first volume production orders for package part burn-in from an AI processor customer, and their first gallium nitride (GaN) customer for high-volume production. Still, weak revenues, cash levels, and other risks weighed on shares.

PRESENTED BY STOCKTWITS
Daily Rip Live With Special Guest Alex King 👑 

Regular co-hosts Shay Boloor and Jordan Lee are joined by special guest Alex King (@CestrianCapitalResearch) to discuss the latest market happenings. Shay and Alex debate Nvidia’s role in the market, how to handle the Quantum stock slump, Tesla and Amazon’s leadership in robotics, and what’s next for Bitcoin as it probes $90k.

Get In Touch 📬

Follow our social channels for great, real-time content on Stocktwits and Twitter. And check out our YouTube channel for in-depth video content! 📲

Help us deliver the best content possible by completing this brief survey. 📝

Email me (Tom Bruni) your feedback; I’d love to hear from you. 📧

Want to sponsor this newsletter and reach hundreds of thousands of passionate investors and traders? Reach us here. 

Terms & Conditions 📝

Securities Disclaimer: STOCKTWITS IS NOT A TAX ADVISOR, BROKER, FINANCIAL ADVISOR OR INVESTMENT ADVISOR. THE SERVICE IS NOT INTENDED TO PROVIDE TAX, LEGAL, FINANCIAL OR INVESTMENT ADVICE, AND NOTHING ON THE SERVICE SHOULD BE CONSTRUED AS AN OFFER TO SELL, A SOLICITATION OF AN OFFER TO BUY, OR A RECOMMENDATION FOR ANY SECURITY. Trading in such securities can result in immediate and substantial losses of the capital invested. You should only invest risk capital, and not capital required for other purposes. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should also consult an attorney or tax professional regarding your specific legal or tax situation. The Content is to be used for informational and entertainment purposes only and the Service does not provide investment advice for any individual. Stocktwits, its affiliates and partners specifically disclaim any and all liability or loss arising out of any action taken in reliance on Content, including but not limited to market value or other loss on the sale or purchase of any company, property, product, service, security, instrument, or any other matter. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Service will not contain a list or description of relevant risk factors. In addition, please note that some of the stocks about which Content is published on the Service have a low market capitalization and/or insufficient public float. Such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information. Read the full terms & conditions here. 🔍

Author Disclosure: The author of this newsletter does not hold positions in any of the securities or assets mentioned. 📋





Want the latest?

Sign up for Tom Bruni's Newsletter below:


Subscribe Here